Redeye believes the progress in Q1 has strengthened BioInvent’s position further ahead of the crucial clinical inflection point for the lead candidate BI-1206 later this year.
ANNONS
Redeye believes the progress in Q1 has strengthened BioInvent’s position further ahead of the crucial clinical inflection point for the lead candidate BI-1206 later this year.